Daiichinkyo Co (STU:D4S) Total Payout Ratio : 0.29 (As of May. 15, 2024)

View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Daiichinkyo Co's current Total Payout Ratio is 0.29.

Daiichinkyo Co Total Payout Ratio Historical Data

The historical data trend for Daiichinkyo Co's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Total Payout Ratio Chart

Daiichinkyo Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Payout Ratio

Get a 7-Day Free Trial

0.32

2.01

0.70

0.43

0.28

Daiichinkyo Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Payout Ratio	Get a 7-Day Free Trial															0.07	0.55	-	0.39	-

Competitive Comparison of Daiichinkyo Co's Total Payout Ratio

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daiichinkyo Co's Total Payout Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Total Payout Ratio falls into.

Daiichinkyo Co Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Daiichinkyo Co's Total Payout Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (-0.154	+	0	+	-411.922)	/	1456.797
	=	0.28

Daiichinkyo Co's Total Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (-0.049	+	0	+	0.375)	/	229.591
	=	-0.00

Daiichinkyo Co Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Daiichinkyo Co (STU:D4S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (STU:D4S) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

DSNKY:USA DSKYF:USA 4568:Japan

Address

3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426

Website

https://www.daiichisankyo.com

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co (STU:D4S) Headlines

No Headlines